Chronic Lower Back Pain Market was worth USD 8.81 Billion in 2022 and is estimated to grow at a CAGR of 5.39% in the forecasted period. The forecasted revenue hints at a growth of around 13.42 billion USD by 2029 The Chronic Lower Back Pain Market is huge, especially in today’s time when back pain is one of the most prominent problems across the world. The Chronic Lower Back Pain market includes a range of products and services, including medications, physical therapy, surgery, and alternative therapies. North America leads the Chronic Lower Back Pain industry and is followed by Europe. US companies like Pfizer and Merck and Co are huge players in the industry. According to WHO, low back pain is a leading cause of disability globally, affecting around 540 million people at any one time. These numbers are increasing rapidly in developing nations where more than 20% of the population faces lower back pain. Aftermath of Covid has changed dimensions of the pharma and healthcare industry. Thus, the rapid growth in the market and increasing cases of Chronic Lower Back Pain, the CAGR of 5.39% justifies itself.To know about the Research Methodology :- Request Free Sample Report Market Drivers in Chronic Lower Back Pain Market One of the important factors has been increasing sedentary lifestyle, where people lose their movement and are stuck in one position which harms the stature of the lower back. Chronic Lower Back Pain lasts more than 3 months and can be painful if not treated. The market for the Chronic Lower Back Pain has significantly increased post 2010s because of increase of use in technologies and a fixed stature throughout. People are preferring treatments on their lower back like cortisone injections, medicines, chiropractic manipulation which helps the market grow rapidly. The chronic lower back pain treatment has shifted its focus and the treatment has been more focused on chiropractic care, and alternative therapies such as acupuncture and massage. Government fundings and awareness campaigns have helped generate awareness amongst people regarding the lower back problems. NSAIDS such as diclofenac, ibuprofen and naproxen are the most commonly used medications for low back pain. The sales of these medicines have increased indicating an upward surge in the chronic lower back pain market. The market has been influenced by advanced technologies that have helped detect the issue swiftly and suggest a treatment accordingly. The treatment offered is diverse - prescription medications, physical therapy, surgery, and alternative therapies make the Chronic Lower Back Pain market more valuable in future. Challenges in Chronic Lower Back Pain market The major challenge for Chronic lower Back Pain industry is long term efficacy of treatments. The treatment may lose its effect after several months, which can recreate the problem of pain. Chronic pain management often requires long-term adherence to treatment plans, which can be challenging for some patients, leading to poor outcomes and increased healthcare costs. Medicines show side effects which can increase other troubles. Evan after spending huge money, a neglect is evident when it comes to lower back pain, which needs to be changed in order to maximize the Chronic Lower Back Pain market share. Chronic Lower Back Pain Market Trend The Chronic lower back pain market has huge potential and is bound to grow to in future looking at current growth. The inclined focus on digital health, such as telemedicine, mobile apps, and wearables, to manage chronic pain conditions like Chronic Lower Back Pain. These technologies can help improve patient engagement, adherence to treatment plans and also increase their focus. Also, with high spendings on R&D, the use of genetics is possible to develop personalized treatment plans for Chronic lower back pain. Regenerative medicines are also been developed which could use Stem cell and plasma to cure the chronic lower back pain by understanding genetic makeup. Thus, the market shows enough potential to withstand the future. A therapeutic approach has been devised which can use a device to stabilize the spine. The device is called ReActiv8 Implantable Neurostimulation System which targets the lumbar multifidus muscle to help cure the lower back pain. Also increasing awareness regarding fitness and health will also make sure that people are inclined towards the market especially when it’s the most faced problem by the youth. The focus of the Chronic Lower Back Pain industry is to reduce this regular pain and stress and compliment a healthy lifestyle with regular work.
Chronic Lower Back Pain: Market Segmentation
Based on Pain Points Discogenic Pain is degenerative conditions related to intervertebral disc and mainly is seen in people who age 30 – 60 yrs old. Lumbar Spinal Stenosis deals with the spinal canal and narrows it inside of the lower back. Stenosis means narrowing which increases pressure on the nerves and increases pain in lower back. Sacroiliac pain affects the sacroiliac joints which damages the lower back and causes stiffness and pain. Facet-Joint Pain is the most common type of chronic pain where the facet joints become painful which in turn damages and hurt lower backBased on diagnosis Clinical history, Physical examination and Imaging guidelines are the 3 types under segmentation by diagnosis. Clinical history and Physical examination are very common during diagnosis of a treatment. It helps in documentation while Imaging guidelines requires the use of technology to assess the body condition via imaging.
Chronic Lower Back Pain Segmentation: By End-User
Hospitals are considered a serious condition in terms of Chronic lower back pain, especially with lesser number of specialised centres. Yet orthopaedic clinics are playing a crucial role in treatment. Many patients have eventually ended up in orthopaedic clinics even after visiting hospitals showcasing the importance of it. Ambulatory Surgery Centres are used in extreme cases where spinal cord or nerves are brutally damaged. Surgery isn’t a preferred and a common option but can be used in emergency casesBy Medication Distribution Channels: Retail distribution of its drugs is very common and is widely preferred. The significant market share can be attributed to the numerous patients who seek chronic lower back pain treatment from hospital and clinics. Online pharmacies to buy drugs related to chronic lower back pain are yet to develop and gain people’s trust, but the segment has huge scope in future
Chronic Lower Back Pain Segmentation: By Region
Global The global chronic lower back pain market is significantly huge, with many established players and new entrants fighting for market share. The established companies have their authority over the market growth and fairly dictate terms in this industry. The significant market share can be attributed to the numerous patients who seek chronic lower back pain diagnosis and treatment immediately at the hospital or clinics. In addition, the sector is anticipated to have significant growth opportunities due to the rising number of treatment methods than easily cure chronic lower back pain. North America is the market leader with big companies like Pfizer and Merck and Co handling the major stake of the chronic lower back pain market. North America North America is leading the market share in chronic lower back pain market because of its technological innovations and higher percentage of population above 30. US is leading the market, as people suffering from chronic lower back pain are increasing due to obesity, sedimentary lifestyle and aged population. The similar problem is seen with its neighbours, Canada which considers chronic lower back pain, a huge concern for many people who are suffering from Chronic lower back pain. Canada has focused on a multi-disciplinary approach where it combines physists, chiropractors and orthoptists to form a solution together. In Mexico, several companies like National Autonomous University of Mexico (UNAM), are involved in the development and marketing of chronic lower pain and its treatment. But the market share for Mexico is lesser than that of its counterparts. Asia Pacific The Chronic Lower Back Pain Market is driven by high potential, above-par population and huge investments in the Chronic lower back pain market. Asia Pacific is showing humongous growth in terms of market share. Thus, the Asia-Pacific market for chronic lower back pain diagnosis and treatment is driven by the increasing demand. The large-scale awareness program and increased demand actually helped the market to flourish. Countries like China, India, Japan, have made sure that the profits and market share increase for Asia pacific region Europe The prevalence of chronic lower back pain infection in Europe is relatively low compared to some other regions. European market for Chronic lower back pain is driven because of sedentary lifestyle and aged population where average age is more than 40. Thus, this results in more cases of chronic lower back pain. Spain experiences huge cases and is one of the most prominent chronic lower back pain markets of Europe. Middle East and Africa The Chronic Lower Back Pain Market is least developed in African continents. Due to negligence, unawareness and improper facilities, the region lacks proper infrastructure to develop a sustainable market. In terms of market share of the Chronic lower back pain industry, its relatively low. People unknowingly suffer which increasing the risk and with no adequate treatment, the market remains untapped. Middle East have recently invested heavily in few institutions and are working upon managing those resources to optimal capacity. Middle East is an emerging market which has high potential South America The market is restricted to few areas of the region like Brazil, Mexico and Argentina. Brazil has numerous specialized clinics, hospitals, and healthcare providers while Mexico has specialized pain management clinics, orthopaedic centres, and a range of healthcare providers dedicated to addressing chronic pain conditions. Thus, South America has potential to earn a larger market share than what they currently.Chronic Lower Back Pain Market Competitive Landscape
The chronic lower back pain market has huge scope especially in current times with increasing sedentary lifestyle and imperfect posture. Thus, the demand is going to increase and with increasing demand, many new players are going to enter the market which has been the case post 2010. Many new startups have started building devices that can track your progress or can help you protect your posture. Medical technology companies are continuously developing innovative devices and technologies for chronic lower back pain management. This can involve spinal implants, minimally invasive surgical tools, neuromodulation devices, and diagnostic imaging technologies aimed at improving diagnosis and treatment outcomes. Also, physiotherapy techniques such as robotic-assisted therapies and innovative exercise programs are used which can be easily adjusted according to patient’s needs. So, if we focus on current competition then Pfizer, Johnson & Johnson, Novartis, Merck, and AstraZeneca compete in pharma sector which includes medication regarding the treatment of chronic lower back pain and pain killers, while Abbott Laboratories, and Boston Scientific compete on medical devices like spinal implants, spinal cord stimulation devices and spend huge money on making those devices as accurate as possible. On the regional level, Drs and Orthopaedic clinics compete to provide best treatment to their patients and suggest a suitable course for the patient to heal. Research and academic institutions also compete and contribute to the development of new treatment approaches, clinical trials, and advancements in chronic lower back pain management and help generate new possible and sustainable measures to cure the patient from chronic lower back pain.
Chronic Lower Back Pain Market Scope: Inquire before buying
Chronic Lower Back Pain Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2017 to 2022 Market Size in 2022: USD 8.81 Bn. Forecast Period 2023 to 2029 CAGR: 5.39% Market Size in 2029: USD 13.42Bn. Segments Covered: by Pain Points 1. Facet-Joint Pain 2. Discogenic Pain 3. Lumbar Spinal Stenosis 4. Sacroiliac pain by Type 1. Clinical history 2. Physical examination 3. Imaging Guidelines by Distribution Channels 1. Retail Pharmacies 2. Online Pharmacies Chronic Lower Back Pain Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Chronic Lower Back Pain Market, Key Players are
1. Pfizer, Inc. (USA) 2. Endo Pharmaceuticals (USA) 3. Johnson & Johnson (USA) 4. Abbott Laboratories (USA) 5. AbbVie, Inc. (USA) 6. Bristol-Myers Squibb (USA) 7. Mylan N.V. (USA) 8. Biogen Inc.(USA) 9. Gilead Sciences, Inc. (USA) 10. Eli Lilly and Company (USA) 11. Merck & Co., Inc. (USA) 12. Purdue Pharma (USA) 13. Mallinckrodt Pharmaceuticals (USA) 14. Boehringer Ingelheim International GmbH (Germany) 15. Bayer AG (Germany) 16. Sanofi (France) 17. AstraZeneca (UK) 18. GlaxoSmithKline (UK) 19. Allergan (Ireland) 20. Medtronic (Ireland) 21. Novartis International AG (Switzerland) 22. F. Hoffmann-La Roche Ltd (Switzerland) 23. Teva Pharmaceutical Industries Ltd. (Israel) 24. Takeda Pharmaceutical Co. Ltd. (Japan) 25. Daiichi Sankyo (Japan) FAQs Q.1) What is the CAGR of Chronic lower back pain market? Ans: The CAGR for Chronic lower back pain market is 5.39% Q.2) Which are the leading companies in Chronic lower back pain market? Ans: Pfizer, AstraZeneca and Merck & Co are some of the leading companies in the Chronic lower back pain market Q.3) Which region shows most potential in future? Ans: Asia Pacific is expected to grow exponentially and has the most potential in future due to increasing demand. Q,4) Which is the leading region in Chronic lower back pain market? Ans: North America leads the market of Chronic lower back pain market significantly Q.5) What was the forecasted period of this report? Ans: The forecasted period for the chronic lower back pain market research was 2023 – 2029
1. Chronic Lower Back Pain Market: Executive Summary 2. Chronic Lower Back Pain Market: Competitive Landscape 2.1. MMR Competition Matrix 2.2. Competitive Landscape 2.3. Key Players Benchmarking 2.4. Market Structure 2.4.1. Market Leaders 2.4.2. Market Followers 2.4.3. Emerging Players 2.5. Consolidation of the Market 3. Chronic lower back pain Market: Dynamics 3.1. Market Trends by region 3.1.1. North America 3.1.2. Europe 3.1.3. Asia Pacific 3.1.4. Middle East and Africa 3.1.5. South America 3.2. Market Drivers by Region 3.2.1. North America 3.2.2. Europe 3.2.3. Asia Pacific 3.2.4. Middle East and Africa 3.2.5. South America 3.3. Market Restraints 3.4. Market Opportunities 3.5. Market Challenges 3.6. PORTER’s Five Forces Analysis 3.7. PESTLE Analysis 3.8. Value Chain Analysis 3.9. Regulatory Landscape by Region 3.9.1. North America 3.9.2. Europe 3.9.3. Asia Pacific 3.9.4. Middle East and Africa 3.9.5. South America 4. Chronic Lower Back Pain Market: Segmentation (by Value USD and Volume Units) 4.1. Chronic lower back pain Market, by Pain Points (2023 – 2029) 4.1.1. Facet-Joint Pain 4.1.2. Discogenic Pain 4.1.3. Lumbar Spinal Stenosis 4.1.4. Sacroiliac pain 4.2. Chronic lower back pain Market, by Type (2023-2029) 4.2.1. Clinical history 4.2.2. Physical examination 4.2.3. Imaging Guidelines 4.3. Chronic lower back pain Market, by Distribution channel (2023-2029) 4.3.1. Retail Pharmacies 4.3.2. Online Pharmacies 4.4. Chronic lower back pain Market, by region (2023-2029) 4.4.1. North America 4.4.2. Europe 4.4.3. Asia Pacific 4.4.4. Middle East and Africa 4.4.5. South America 5. North America Chronic lower back pain Market (by Value USD and Volume Units) 5.1. North America Chronic lower back pain Market, by Pain Points (2023-2029) 5.1.1. Facet-Joint Pain 5.1.2. Discogenic Pain 5.1.3. Lumbar Spinal Stenosis 5.1.4. Sacroiliac pain 5.2. North America Chronic lower back pain Market, by Type (2023-2029) 5.2.1. Clinical history 5.2.2. Physical examination 5.2.3. Imaging Guidelines 5.3. North America Chronic lower back pain Market, by Distribution channel (2023-2029) 5.3.1. Retail Pharmacies 5.3.2. Online Pharmacies 5.4. North America Chronic lower back pain Market, by Country (2022-2030) 5.4.1. United States 5.4.2. Canada 5.4.3. Mexico 6. 7. Europe Chronic lower back pain Market (by Value USD and Volume Units) 6.1. Europe Chronic lower back pain Market, by Pain Points (2023-2029) 6.2. Europe Chronic lower back pain Market, by Type (2023-2029) 6.3. Europe Chronic lower back pain Market, by Distribution channel (2023-2029) 6.4. Europe Chronic lower back pain Market, by Country (2023-2029) 6.4.1. UK 6.4.2. Netherlands 6.4.3. Germany 7. Asia Pacific Chronic lower back pain Market (by Value USD and Volume Units) 7.1. Asia Pacific Chronic lower back pain Market, by Pain Points (2023-2029) 7.2. Asia Pacific Chronic lower back pain Market, by Type (2023-2029) 7.3. Asia Pacific Chronic lower back pain Market, by Distribution channel (2023-2029) 7.4. Asia Pacific Chronic lower back pain Market, by Country (2022-2030) 7.4.1. China 7.4.2. S Korea 7.4.3. Japan 7.4.4. India 8. Middle East and Africa Chronic lower back pain Market (by Value USD and Volume Units) 8.1. Middle East and Africa Chronic lower back pain Market, by Pain Points (2023-2029) 8.2. Middle East and Africa Chronic lower back pain Market, by Type (2023-2029) 8.3. Middle East and Africa Chronic lower back pain Market, by Distribution channel (2023-2029) 8.4. Middle East and Africa Chronic lower back pain Market, by Country (2023-2029) 8.4.1. UAE 8.4.2. South Africa 8.4.3. Saudi Arabia 8.4.4. Morocco 9. South America Chronic lower back pain Market (by Value USD and Volume Units) 9.1. South America Chronic lower back pain Market, by Pain Points (2023-2029) 9.2. South America Chronic lower back pain Market, by Type (2023-2029) 9.3. South America Chronic lower back pain Market, by Distribution channel (2023-2029) 9.4. South America Chronic lower back pain Market, by Country (2023-2029) 9.4.1. Brazil 9.4.2. Argentina 10. Company Profile: Key players 10.1. AstraZeneca 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Business Portfolio 10.1.4. SWOT Analysis 10.1.5. Business Strategy 10.1.6. Recent Developments 10.1.7. Pfizer, Inc. (USA) 10.1.8. Endo Pharmaceuticals (USA) 10.1.9. Johnson & Johnson (USA) 10.1.10. Abbott Laboratories (USA) 10.1.11. AbbVie, Inc. (USA) 10.1.12. Bristol-Myers Squibb (USA) 10.1.13. Mylan N.V. (USA) 10.1.14. Biogen Inc. (USA) 10.1.15. Gilead Sciences, Inc. (USA) 10.1.16. Eli Lilly and Company (USA) 10.1.17. Merck & Co., Inc. (USA) 10.1.18. Purdue Pharma (USA) 10.1.19. Mallinckrodt Pharmaceuticals (USA) 10.1.20. Boehringer Ingelheim International GmbH (Germany) 10.1.21. Bayer AG (Germany) 10.1.22. Sanofi (France) 10.1.23. GlaxoSmithKline (UK) 10.1.24. Allergan (Ireland) 10.1.25. Medtronic (Ireland) 10.1.26. Novartis International AG (Switzerland) 10.1.27. F. Hoffmann-La Roche Ltd (Switzerland) 10.1.28. Teva Pharmaceutical Industries Ltd. (Israel) 10.1.29. Takeda Pharmaceutical Co. Ltd. (Japan) 10.1.30. Daiichi Sankyo (Japan) 11. Key Findings 12. Industry Recommendation